SCHEMBL5359935

SCHEMBL5359935

Nc1nccc(C(=O)NCC2CCN(C(=O)OCc3ccccc3)CC2)n1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 14/20 0.61
CYP2D6 P10635 4/20 0.57
CYP2C9 P11712 4/20 0.57
CYP3A4 P08684 3/20 0.56
TPSAB1 Q15661 2/20 0.54
TPSD1 Q9BZJ3 2/20 0.54
TPSG1 Q9NRR2 2/20 0.54
F2 P00734 1/20 0.54
PLG P00747 1/20 0.54
PRSS1 P07477 1/20 0.54
PRSS2 P07478 1/20 0.54
PRSS3 P35030 1/20 0.54
NAPEPLD Q6IQ20 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
CYP2C19 P33261 1/20 0.50
FAAH O00519 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362985 0.91 GRIN2B (0.61) GRIN2BCYP2D6CYP2C9TPSAB1TPSD1
SCHEMBL5368020 0.89 GRIN2B (0.62) GRIN2BCYP2D6CYP2C9CYP3A4TPSAB1
SCHEMBL5371193 0.87 GRIN2B (0.59) GRIN2BCYP2D6CYP2C9CYP3A4TPSAB1
SCHEMBL5358468 0.87 GRIN2B (0.64) GRIN2BCYP2D6CYP2C9CYP3A4TPSAB1
SCHEMBL5368572 0.87 GRIN2B (0.67) GRIN2BCYP2D6CYP2C9CYP3A4
SCHEMBL5366757 0.87 NAPEPLD (0.60) GRIN2BCYP2D6CYP2C9CYP3A4TPSAB1
SCHEMBL5378539 0.86 GRIN2B (0.59) GRIN2BCYP2D6CYP2C9CYP3A4TPSAB1
SCHEMBL5368092 0.85 GRIN2B (0.57) GRIN2BCYP2D6CYP2C9CYP3A4TPSAB1
SCHEMBL5368320 0.84 GRIN2B (0.72) GRIN2BCYP2D6CYP2C9CYP3A4TPSAB1
SCHEMBL5369615 0.83 GRIN2B (0.61) GRIN2BCYP2D6CYP2C9CYP3A4TPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259157-B2 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK & CO., INC. (US) 2007-08-21 US disclosed
US-7259157-B2 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK & CO., INC. (US) 2007-08-21 US disclosed
US-7259157-B2 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK & CO., INC. (US) 2007-08-21 US disclosed
EP-1390034-A4 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2005-07-13 EP disclosed
EP-1390034-A1 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2004-02-25 EP disclosed
US-20030119811-A1 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK SHARP & DOHME CORP. 2003-06-26 US disclosed
WO-2002080928-A1 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119811-A1 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists GRIN1, GRIN2B, GRIN2A GRIN2B 2/4885CYP2D6 3153/4885CYP2C9 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.